louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06565520: Modulating Cortical Excitability to Improve Functional Movements in Individuals With Patellofemoral Pain
Official title: Modulating Cortical Excitability to Improve Functional Movements in Individuals With Patellofemoral Pain: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Lead sponsor: University of Nevada, Las Vegas
Sponsor class: OTHER
First posted: 2024-08-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study sought to investigate whether modulation of cortical excitability of the gluteal musculature, via tDCS paired with exercise, will reduce the amount the knee caves in during functional tasks in individuals with PFP. The objective is the explore if having tDCS target the area of the brain controlling hip muscles, when paired with exercise, will be more effective in reducing the amount the knee caves in for individuals with PFP versus those who receive exercise alone as their treatment. The aim is to contribute our findings to the growing knowledge in this area in order to help establish the possibility, and feasibility, of its use in clinical settings to strengthen traditional treatments for this patient population.


Eligibility criteria: Inclusion Criteria:

1. are between 18 and 45 years old
2. have had patellofemoral pain (PFP; kneecap pain) on one side for at least 3 months, and 3) the knee does cave in when performing functional movements.

Exclusion Criteria:

1. do not have pain coming from the kneecap during screening;
2. have a history of knee injury or surgery,
3. have a history of seizures and/or taking anti-seizure medication,
4. have an implanted device that interacts with electric current,
5. have a history of balance disorder,
6. currently are pregnant or think they may be pregnant.

Primary outcomes:
measure: trunk lean angle
timeFrame: Baseline and Immediately after intervention
measure: knee frontal plane projection angle
timeFrame: Baseline and Immediately after intervention
measure: hip frontal plane projection angle
timeFrame: Baseline and Immediately after intervention
measure: dynamic valgus index
timeFrame: Baseline and Immediately after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: University of Nevada, Las Vegas
state: Nevada
Study officials:
affiliation: UNLV
name: Kai Yu Ho, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06828120: A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects
Official title: A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Lead sponsor: Bun Yao Biotechnology Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: Clinny biotech limited
name: Taipei Veterans General Hospital, Taiwan
First posted: 2025-02-14
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.

Detailed description: The study will enroll 40\~60 patients and complete 40 patients.

Eligibility criteria: Inclusion Criteria:

* Subjects aged older than 20\~75 years old.
* Able to sign informed consent prior to the study.
* The appearance of sputum and the difficulty of expectoration are both at level 2 or above.

Exclusion Criteria:

* Subjects with known hypersensitivity to Acetylcysteine preparations.
* Subjects with other serious medical diseases that are judged by the attending physician to affect the evaluation results (such as: tuberculosis, pneumonia, bronchial asthma, bronchiectasis, cor pulmonale, lung cancer, acute myocardial infarction, acute hepatitis, renal failure, etc.)
* Pregnancy or breast-feeding woman.
* Female subjects or their sexual partners do not use contraception during the trial.
* Joining any drug clinical trial within 3 months prior to dosing.
* Investigator considered to be inappropriate for enrollment.

Primary outcomes:
measure: To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600MG granules administered twice daily for 14 days in treatment of COPD Disease.
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
References:
Clinical trial NCT04719520: Efficiency Analysis of Wireless Vibrating Caller During Surgery
Official title: Efficiency Analysis of Wireless Vibrating Caller Compared With Traditional Broadcasting in Contacting Patients' Family Members During Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Communication
Keywords: Operating room; Telecommunication experts
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 68
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a comparative study of the benefits of different ways of contacting patients' family members during surgery.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: As the number of operation increases, it is important to control of the utilization rate of the operating room. This study is a comparative study of the benefits of different ways of contacting patients' family members during surgery.

Detailed description: As the number of operation increases, it is important to control of the utilization rate of the operating room. When family members need to be contacted during the operation, whether family members in the waiting area can be notified in time will affect the overall operation time of the patient and the utilization rate of the operating room. The way of contact also indirectly affects issues such as hospital costs and patient privacy. This study is a comparative study of the benefits of different ways of contacting patients' family members during surgery.

This study will compare the current traditional method (using radio and telephone to notify the patient's family to the operating room) or the wireless vibrating caller to notify the patient's family to the operating room, and analyze the variables generated by the two different methods including demand time of notification, acceptance, and patient privacy issues. The results of the study will use scientific data to prove which way to notify the patient's family is more efficient and a good way to take into account of the patient's privacy.

Eligibility criteria: Inclusion criteria:

* The care family of surgical patients

Exclusion criteria:

.The surgical patient's care family has the problems of impaired hearing activity or walking disability.

Primary outcomes:
measure: demand time
timeFrame: 1 day
Secondary outcomes:
measure: acceptance
timeFrame: 1 day
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital Yunlin Branch
name: Pei-Ming Huang, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00646620: Symbicort Onset of Action 1
Official title: A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: asthma
bronchodilatation
Symbicort
budesonide/formoterol
Advair Diskus
Ventolin
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-03-28
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma


Eligibility criteria: Inclusion Criteria:

* Diagnosis of asthma and baseline lung function test results as determined by protocol
* Required and received asthma maintenance therapy within previous 4 weeks at doses determined by protocol

Exclusion Criteria:

* Severe asthma or asthma markedly affected by seasonal factors
* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Primary outcomes:
measure: FEV1 3 minutes post dose
timeFrame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
Secondary outcomes:
measure: 12 hour serial FEV1
timeFrame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
measure: Patients perception of effect
timeFrame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Catherine Bonuccelli
role: STUDY_DIRECTOR
References:
Clinical trial NCT05802420: The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Official title: The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pancreatic Cancer
Advanced Cancer
Metastatic Cancer
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2023-04-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it aims to answer are:

* prognostic value of baseline MRD;
* the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before first-line chemotherapy initiation and at the first imaging assessment after chemotherapy.


Eligibility criteria: Inclusion Criteria:

* patients with histologically confirmed unresectable advanced or metastatic pancreatic cancer;
* both sexes, age ≥18 years old;
* ECOG performance status score ≤2;
* the expected survival time was ≥3 months.

Exclusion Criteria:

* a known diagnosis of pancreatic cancer other than ductal adenocarcinoma;
* treated with any systemic antitumor treatment before first-line chemotherapy onset;
* died or lost to follow-up within one month after the initiation of first-line chemotherpay;
* combined with other primary malignances.

Primary outcomes:
measure: Progression-free survival
timeFrame: Baseline until death from any cause (up to approximately 24 months)
Secondary outcomes:
measure: Overall survival
timeFrame: Baseline until death from any cause (up to approximately 24 months)
Other outcomes:
measure: The prognostic value of MRD
timeFrame: Baseline until death from any cause (up to approximately 24 months)
measure: The prognostic role of targeted therapy selected based on MRD
timeFrame: Baseline until death from any cause (up to approximately 24 months)
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Chunmei Bai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06023420: Efficacy of a Herbal Formula for Bone Metastases
Official title: Using A Special 4 Herbs Formula For The Palliative Care Of Patients Suffering From Bone Secondaries
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Bone Metastases
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2023-09-05
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: RATIONALE: Nearly 50% of patients with bone metastases develop one or more complications collectively termed skeletal-related events (SREs). The study herbal medicine might reduce the morbidities due to "Skeletal-related events" (SRES), and extend survival time.

PURPOSE: the study is to explore the effects of the 4 Herbs Formula on the reduction of "Skeletal-related events" (SRES), and survival time.

Detailed description: OBJECTIVES:

Primary Primary efficacy end points are SRE, general state and biomarkers. Secondary Survival rate and survival time Time to first SRE (since randomization) Biochemical markers Quality of Life: EQ5-D Pain control (Brief Pain Inventory)

OUTLINE:

Patients will be randomized to receive either 4 herbs formula plus Zometa or Zometa alone after all the eligibility criteria have been fulfilled and informed consent has been signed.

Eligibility criteria: Inclusion Criteria:

* Aged 18 years or older
* Breast cancer bone metastasis-no supplementary treatment or hormonal treatment alone
* Confirmed diagnosis of metastatic breast cancer
* Radiographic proof of metastatic bone disease
* Informed consent obtained

Exclusion Criteria:

* Known history of primary bone tumors (benign and/or malignant)
* Prior use of bone modifying agents, including but not limited to zoledronic acid or denosumab within 12 months of study entry
* Active anti-cancer therapies in the form of cytotoxics or targeted therapies. \[Patients who are currently on hormonal therapies, including but not limited to tamoxifen, aromatase inhibitors and LHRH agonists/antagonists are allowed for study entry. Clarifications shall be sought from investigators if in doubt\].
* Significant drug hypersensitivity
* No informed consent signed

Primary outcomes:
measure: reducing the morbidities of "Skeletal-related events" (SRES) extending survival time
timeFrame: 3 months
Secondary outcomes:
measure: Survival rate and survival time
timeFrame: Proportion of participants in all groups with overall survival at 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01750320: Koning Breast Computed Tomography Guided Biopsy
Official title: Koning Breast CT-guided Biopsy Phase I Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Breast Cancer
Keywords: Breast CT
Biopsy
Lead sponsor: Koning Corporation
Sponsor class: INDUSTRY
Collaborators: name: Elizabeth Wende Breast Care, LLC
First posted: 2012-12-17
Enrollment: 4
Sex: FEMALE
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The primary aim of this study is to show that the accuracy of Koning Breast CT-guided biopsy is at least equivalent to that of stereotactic-guided biopsy.


Eligibility criteria: Inclusion Criteria:

* Female at least 35 years of age of any ethnicity
* Lesion seen on mammography
* Diagnostic report read as BI-RADS 4 or 5
* Will undergo biopsy no later than four weeks from date of mammogram
* Is able to undergo informed consent

Exclusion Criteria:

* Pregnancy
* Lactation
* Subjects with breast implants
* Subjects with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pacemaker.
* Subjects who are unable to tolerate study constraints.
* Subjects who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to)

  * Treatment for enlarged thymus gland as an infant
  * Irradiation for benign breast conditions, including breast inflammation after giving birth
  * Treatment for Hodgkins disease
* Subjects who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
* Subjects who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

  * Tuberculosis
  * Severe scoliosis

Primary outcomes:
measure: The accuracy of Koning breast CT-guided biopsy
timeFrame: about 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Elizabeth Wende Breast Care
state: New York
Study officials:
References:
Clinical trial NCT03141320: Confident Birthing: What Influences Women's Confidence for Birth?
Official title: Confident Birthing: A Qualitative Study Exploring the Influences on Women's Confidence for Birth During Pregnancy and Labour
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy
Labour
Birth
Psychosocial Wellbeing
Woman's Health
Lead sponsor: University of Southampton
Sponsor class: OTHER
Collaborators: name: Hampshire Hospitals NHS Foundation Trust
First posted: 2017-05-05
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnant women or women that have given birth within the last two years

Brief summary: This is a grounded theory study aiming to understand women's perception of what influences their confidence for birth during labour and birth. Data is being collected using interviews and social media sources.

Detailed description: This study aims to help women have a better birth experience, by trying to understand what a 'confident birth' means to women during pregnancy and labour. Results from a recent service evaluation at a local NHS Trust, exploring a new programme designed to enhance women's birth experience, highlighted the importance of understanding women's confidence for birth. A significant number of pregnant women that attended the course (19.5%) felt 'not at all confident' for birth. The service evaluation results also suggested that confidence for birth is an important influence of enhancing birth experience.

There is some research that suggests that if women's confidence for birth can be improved, then she may be less fearful of birth and have experience less labour pain. However, very little is known about what women consider to be a 'confident birth' and who or what they feel influences their confidence. If maternity services are able to understand this, this could possibly lead to the development of tools and strategies to help women to feel more confident for giving birth.

This is a qualitative study that involves two methods of data collection: interviews and social media. Women that are pregnant or have recently given birth will be interviewed to explore who or what they feel has influenced their confidence for birth. The interviews will last for about one and a half hours. The location for interview is flexible and women can be interviewed in their own home. In addition to this, approximately 500 messages posted on a large UK parenting website about confidence for birth will also be analysed.

Eligibility criteria: Inclusion Criteria:

* given birth within the last two years or are pregnant
* consider themselves well enough to take part in the study
* have received maternity care from specific NHS Trust

Exclusion Criteria:

* under 18 years old
* have not received maternity care from specific NHS Trust

Primary outcomes:
measure: Semi-structured interviews
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04241120: Feasibility Study for Treating Trichotillomania With Wearable Device and App System
Official title: Feasibility Study for Treating Trichotillomania With Wearable Device and App System Using Habit Reversal Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trichotillomania
Keywords: Hair Pulling Disorder
Body-Focused Repetitive Behaviors
Trichotillomania
Lead sponsor: HabitAware Inc.
Sponsor class: INDUSTRY
Collaborators: name: Marquette University
name: National Institute of Mental Health (NIMH)
First posted: 2020-01-27
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop. Behavioral based therapies focused on increasing awareness of hair pulling followed by the use of an incompatible behavior have proven effective. In an effort to enhance awareness, a wrist worn motion detection device was created. In this study, we will test the feasibility of the HabitAware device and accompanying app as a system for delivering self-administered habit reversal training (HRT).


Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older
2. Speak fluent English
3. Current diagnosis of TTM
4. Score above the normative mean on the automatic pulling subscale of the MIST-A
5. Not on psychotropic medication or on a stable dose (i.e., same dose for past 6 weeks)

Exclusion Criteria:

1. Currently receiving psychotherapy
2. Other psychiatric condition requiring more immediate care
3. Have previously used any behavior awareness devices (e.g. Keen)

Primary outcomes:
measure: Percentage of Participants in the HabitAware Condition That Wore the Device for 6 Hours Per Day and More Than 4 Days Per Week.
timeFrame: Four weeks
Secondary outcomes:
measure: Percentage of Participants That Reported the Device >3 on a Scale of 1-5 for Accuracy.
timeFrame: Four weeks
measure: Number of Participants That Can Implement HRT Procedures With 80% Accuracy
timeFrame: Four weeks
measure: Number of Participants With 30% Improvement in Clinical Symptoms
timeFrame: Four weeks
Other outcomes:
Locations:
city: Saint Louis Park
country: United States
facility: HabitAware, Inc.
state: Minnesota
Study officials:
References: